Promising antitumor activity with MGCD0103, a novel isotype-selective histone deacetylase inhibitor

Expert Opinion on Investigational Drugs

Volumn 17, Issue 8, 2008, Pages 1247-1254

  Le Tourneau, Christophe ^a   Siu, Lillian L ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Cancer; HDAC inhibitor; Hodgkin's lymphoma; Isotype selectivity; Pharmacodynamics; Pharmacokinetic

Indexed keywords

ANTINEOPLASTIC AGENT; AZACITIDINE; GEMCITABINE; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; N (2 AMINOPHENYL) 4 [4 (3 PYRIDINYL) 2 PYRIMIDINYLAMINOMETHYL]BENZAMIDE; VORINOSTAT; BENZAMIDE DERIVATIVE; ISOENZYME; N (2 AMINOPHENYL) 4 ((4 PYRIDIN 3 YLPYRIMIDIN 2 YLAMINO)METHYL)BENZAMIDE; N-(2-AMINOPHENYL)-4-((4-PYRIDIN-3-YLPYRIMIDIN-2-YLAMINO)METHYL)BENZAMIDE; PYRIMIDINE DERIVATIVE;

ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; BLOOD TOXICITY; CARBONATED BEVERAGE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DEEP VEIN THROMBOSIS; DEHYDRATION; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG EFFICACY; DRUG ELIMINATION; DRUG FATALITY; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; EDEMA; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SUBSTRATE COMPLEX; EVIDENCE BASED MEDICINE; FATIGUE; FEBRILE NEUTROPENIA; FOOD DRUG INTERACTION; GASTROINTESTINAL SYMPTOM; HEMATOLOGIC MALIGNANCY; HUMAN; HYPOKALEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; LIVER FUNCTION TEST; LIVER TOXICITY; LOW DRUG DOSE; LYMPHOCYTOPENIA; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MEDLINE; MENTAL HEALTH; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NONHUMAN; PERICARDIAL EFFUSION; PHARMACODYNAMICS; PNEUMONIA; QRS COMPLEX; QT PROLONGATION; RECOMMENDED DRUG DOSE; REVIEW; SEPSIS; SIDE EFFECT; SOLID TUMOR; THROMBOCYTOPENIA; URINARY FREQUENCY; VOMITING; WEAKNESS; ANIMAL; CELL PROLIFERATION; DRUG ANTAGONISM; DRUG EFFECT; ENZYME SPECIFICITY; NEOPLASM; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; BENZAMIDES; CELL LINE, TUMOR; CELL PROLIFERATION; CLINICAL TRIALS AS TOPIC; HISTONE DEACETYLASES; HUMANS; ISOENZYMES; NEOPLASMS; PYRIMIDINES; SUBSTRATE SPECIFICITY;

EID: 51449095189     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.17.8.1247     Document Type: Review

References (44)

1. Fraga MF, Ballestar E, Villar-Garea A, et al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet 2005;37:391-400
2. Esteller M. Epigenetics in cancer. N Engl J Med 2008;358:1148-59
3. Grunstein M. Histone acetylation in chromatin structure and transcription. Nature 1997;389:349-52
4. Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 2006;6:38-51
5. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006;5:769-84
6. Tryndyak VP, Kovalchuk O, Pogribny IP. Loss of DNA methylation and histone H4 lysine 20 trimethylation in human breast cancer cells is associated with aberrant expression of DNA methyltransferase 1, Suv4-20h2 histone methyltransferase and methyl-binding proteins. Cancer Biol Ther 2006;5:65-70
7. Pogribny IP, Ross SA, Tryndyak VP, et al. Histone H3 lysine 9 and H4 lysine 20 trimethylation and the expression of Suv4-20h2 and Suv-39h1 histone methyltransferases in hepatocarcinogenesis induced by methyl deficiency in rats. Carcinogenesis 2006;27:1180-6
8. Seligson DB, Horvath S, Shi T, et al. Global histone modification patterns predict risk of prostate cancer recurrence. Nature 2005;435:1262-6
9. Gregoretti IV, Lee YM, Goodson HV. Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. J Mol Biol 2004;338:17-31
10. Xu WS, Parmigiani RB, Marks PA. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 2007;26:5541-52
11. Dokmanovic M, Clarke C, Marks PA. Histone deacetylase inhibitors: overview and perspectives. Mol Cancer Res 2007;5:981-9
12. Peart MJ, Smyth GK, van Laar RK, et al. Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. Proc Natl Acad Sci USA 2005;102:3697-702
13. Gui CY, Ngo L, Xu WS, et al. Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1. Proc Natl Acad Sci USA 2004;101:1241-6
14. Liang D, Kong X, Sang N. Effects of histone deacetylase inhibitors on HIF-1. Cell Cycle 2006;5:2430-5
15. Ungerstedt JS, Sowa Y, Xu WS, et al. Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc Natl Acad Sci USA 2005;102:673-8
16. Itoh Y, Suzuki T, Miyata N. Isoform-selective histone deacetylase inhibitors. Curr Pharm Des 2008;14:529-44
17. Olsen EA, Kim YH, Kuzel TM, et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 2007;25:3109-15
18. Fischer A, Sananbenesi F, Wang X, et al. Recovery of learning and memory is associated with chromatin remodelling. Nature 2007;447:178-82
19. Cao H. Pharmacological induction of fetal hemoglobin synthesis using histone deacetylase inhibitors. Hematology 2004;9:223-33
20. Routy JP. Valproic acid: a potential role in treating latent HIV infection. Lancet 2005;366:523-4
21. Fournel M, Bonfils C, Hou Y, et al. MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has a broad-spectrum antitumor activity in vitro and in vivo. Mol Cancer Ther 2008;7:759-68
22. Siu LL, Pili R, Duran I, et al. Phase I study of MGCD0103 given as a 3-times-per-week oral dose in patients with advanced solid tumors. J Clin Oncol 2008;26:1940-7
23. Lancet JE, Nichols G, Assouline S, et al. A phase I study of MGCD0103 given as a twice weekly oral dose in patients with advanced leukemias or myelodysplastic syndromes (MDS). Proc Am Soc Clin Oncol 2008 [abstract 2516]
24. Bociek RG, Kuruvilla J, Pro B, et al. Isotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 demonstrates clinical activity and safety in patients with relapsed/refractory classical Hodgkin Lymphoma (HL). Proc Am Soc Clin Oncol 2008 [abstract 8507]
25. Kelly WK, O'Connor OA, Krug LM, et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 2005;23:3923-31
26. Gojo I, Jiemjit A, Trepel JB, et al. Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias. Blood 2007;109:2781-90
27. Ryan QC, Headlee D, Acharya M, et al. Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. J Clin Oncol 2005;23:3912-22
28. Bonfils C, Kalita A, Dubay M, et al. Evaluation of the pharmacodynamic effects of MGCD0103 from preclinical models to human, using a novel HDAC enzyme assay. Clin Cancer Res 2008;14:3441-9
29. Hurwitz H, Nelson B, O'Dwyer J, et al. Phase I/II: the oral isotype-selective HDAC inhibitor MGCD0103 in combination with gemcitabine (GEM) in patients with solid tumors (MGCD0103-006 Trial). Proc Am Soc Clin Oncol 2008 [abstract 4625]
30. Garcia-Manero G, Assouline S, Cortes J, et al. Phase I study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia. Blood 2008; [Epub ahead of print]
31. Garcia-Manero G, Yang AS, Klimek V, et al. Phase I/II study of MGCD0103, an oral isotype-selective histone deacetylase (HDAC) inhibitor, in combination with 5-azacitidine in higher-risk myelodysplastic syndrome (MDS) and acute myelogenous leukemia (AML) [abstract 444]. Proc Am Soc Hematol 2007
32. Crump M, Andreadis C, Assouline S, et al. Treatment of relapsed or refractory non-hodgkin lymphoma with the oral isotype-salective histone deacetylase inhibitor MGCD0103: interim results from a phase II study. Proc Am Soc Clin Oncol 2008 [abstract 8528]
33. Gelmon K Tolcher A, Carducci M, et al. Phase I trial of the oral histone deacetylase (HDAC) inhibitor MGCD0103 given either daily or 3x weekly for 14 days every 3 weeks in patients (pts) with advanced solid tumors [abstract 3147]. Proc Am Soc Clin Qncol 2005
34. Nguyen H, Gravel S, MacLeod AR. Synergistic antitumor activity of the isotype-selective histone deacetylase inhibitor MGCD0103 in combination with gemcitabine. Proceedings of the AACK-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; 14-18 November 2005, Philadelphia, Pennsylvania, USA. Clin Cancer Res 2005;11(24):9153s
35. Karagiannis TC, El-OstaA. Will broad-spectrum histone deacetylase inhibitors be superseded by more specific compounds? Leukemia 2007;21:61-5
36. Glaser KB, Li J, Staver MJ, et al. Role of class I and class II histone deacetylases in carcinoma cells using siRNA. Biochem Biophys Res Commun 2003;310:529-36
37. Lagger G, O'Carroll D, Rembold M, et al. Essential function of hiscone deacetylase 1 in proliferation control and CDK inhibitor repression. EMBO J 2002;21:2672-81
38. Vannini A, Volpari C, Filocamo G, et al. Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor. Proc Natl Acad Sci USA 2004;101:15064-9
39. Balasubramanian S, Ramos J, Luo W, et al. A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas. Leukemia 2008;22:1026-34
40. Huang BH, Laban M, Leung CH, et al. Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1/WAF1 expression, independent of historic deacetylase 1. Cell Death Differ 2005;12:395-404
41. Itoh Y, Suzuki T, Kouketsu A, et al. Design, synthesis, structure-selectivity relationship, and effect on human cancer cells of a novel series of historic deacetylase 4-selective inhibitors. J Med Chem 2007;50:5425-38
42. Schafer S, Saunders L, Eliseeva E, et al. Phenylalanine-containing hydroxamic acids as selective inhibitors of class, IIb histone deacetylases (HDACs). Bioorg Med Chem 2008;16:2011-33
43. Shah MH, Binkley P, Chan K, et al. Cardiotoxicity of histone deacetylase inhibitor depsipeptide in patients with metastatic neuroendocrine tumors. Clin Cancer Res 2006;12:3997-4003
44. Piekarz RL, Frye AR, Wright JJ, et al. Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma. Clin Cancer Res 2006;12:3762-73